Summary

China Lung Cancer Screening Market Trends

The China lung cancer screening market size was estimated at USD 554.17 million in 2024, and is projected to reach USD 1,492.56 million by 2033, growing at a CAGR of 11.83% from 2025 to 2033. Several key factors drive market growth, including the high prevalence of lung cancer, advances in screening technology, supportive government policies, and increasing awareness about early detection.According to the Shanghai Municipal People's Government, in June 2024, lung cancer was observed as one of the most common and deadliest tumors in China, with approximately 800,000 new cases reported annually and around 70.0% of patients diagnosed at advanced or terminal stages, highlighting the urgent need for effective screening solutions to improve early diagnosis and treatment outcomes.

Lung cancer is the leading cause of cancer incidence and mortality worldwide, and China carries the heaviest burden. Each year, an estimated 1.06 million new cases and 0.73 million deaths are attributed to lung cancer in the country, underscoring its status as a formidable public health challenge. Survival outcomes are strongly linked to stage at diagnosis: patients detected at stage IA have a 5-year survival rate of ~82%, compared to just ~7% in stage IVB, making early detection critical.

Historically, lung cancer in China has been diagnosed late, as early-stage disease presents few symptoms. Randomized controlled trials such as NLST (U.S.) and NELSON (Europe) demonstrated that low-dose CT (LDCT) screening can significantly reduce mortality. However, conventional LDCT presents challenges of false positives, overdiagnosis, and missed detection in high-risk groups not covered by international criteria. China has advanced localized screening protocols tailored to its population to address this. Risk factor profiling in western China-covering smoking, COPD, pulmonary fibrosis, and prior malignancies-has enabled more precise identification of high-risk cohorts.

China Lung Cancer Screening Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the China lung cancer screening market report based on cancer, diagnosis, and end use:
• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)
• Diagnosis Outlook (Revenue, USD Million, 2021 - 2033)
• Low Dose Spiral CT Scan
• Chest X-ray
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals and Clinics
• Diagnostic Centers
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Cancer
1.2.2. Diagnosis
1.2.3. End use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Cancer outlook
2.2.2. Diagnosis outlook
2.2.3. End use outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. China Lung Cancer Screening Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. China Lung Cancer Screening Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. China Lung Cancer Screening Market: Cancer Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. China Lung Cancer Screening Market: Cancer Movement Analysis
4.3. China Lung Cancer Screening Market by Cancer Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analysis, 2021 to 2033 for the following
4.5. Non-small Cell Lung Cancer (NSCLC)
4.5.1. Non-small Cell Lung Cancer (NSCLC) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Small Cell Lung Cancer (SCLC)
4.6.1. Small Cell Lung Cancer (SCLC) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. China Lung Cancer Screening Market: Diagnosis Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. China Lung Cancer Screening Market: Diagnosis Movement Analysis
5.3. China Lung Cancer Screening Market by Diagnosis Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analysis, 2021 to 2033 for the following
5.5. Low Dose Spiral CT Scan
5.5.1. Low Dose Spiral CT Scan Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Chest X-ray
5.6.1. Chest X-ray Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. China Lung Cancer Screening Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. China Lung Cancer Screening Market: End Use Movement Analysis
6.3. China Lung Cancer Screening Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analysis, 2021 to 2033 for the following
6.5. Hospitals and Clinics
6.5.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Diagnostic Centers
6.6.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Others
6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Biodesix
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. DELFI Diagnostics, Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. GE HealthCare
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Siemens Healthineers AG
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Koninklijke Philips N.V.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. CANON MEDICAL SYSTEMS CORPORATION
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Medtronic
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Shanghai United Imaging Healthcare Co., LTD
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Freenome Holdings, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives